The 13 most recent market catalysts affecting $PYXS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintained an 'Outperform' rating on Pyxis Oncology and raised the price target from $6 to $8. This action signals increased confidence from the ana…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on Pyxis Oncology and raised the price target from $7 to $8. This action signals continued analyst conf…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology announced updated Phase 1 trial data for its drug MICVO, touting 'promising efficacy and safety.' However, a William Blair analyst pointed out that 54% of patients e…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19
Wells Fargo analyst Derek Archila has updated their outlook on Pyxis Oncology, raising the price target from $12 to $19 and reiterating an 'Overweight' rating. This action signals …
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 85
Pyxis Oncology shares are trading lower after the company announced updated data from its ongoing global Phase 1 monotherapy study evaluating MICVO in patients with 2L+ R/M head and neck squamous cell carcinoma.
The headline indicates a significant negative reaction to updated clinical trial data for Pyxis Oncology's lead candidate, MICVO. While the specific details of the 'updated data' a…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
Pyxis Oncology Announces Updated Data From Ongoing Global Phase 1 Monotherapy Study Evaluating Micvotabart Pelidotin In Patients With 2L+ R/M Head And Neck Squamous Cell Carcinoma
Pyxis Oncology's announcement of strong Phase 1 data for MICVO in a difficult-to-treat cancer like HNSCC is a major positive catalyst. The reported 36% confirmed objective response…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology's stock surged over 5% overnight following two key announcements. First, the appointment of Thomas Civik as permanent CEO and Chairman is a positive signal, given hi…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Pyxis Oncology shares are trading higher after the company announced that it will present its updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma.
This headline represents a significant positive catalyst for Pyxis Oncology. Positive clinical data, especially from a Phase 1 study showing efficacy in a difficult-to-treat cancer…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 75
Pyxis Oncology To Present Updated Phase 1 MICVO Data In Head And Neck Cancer On A Live Webcast On September 9, 2026 At 7:30 a.m. ET
Pyxis Oncology is hosting a live webcast on September 9, 2026, to present updated Phase 1 clinical data for micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Pyxis Oncology Appoint Thomas Civik Chairman, CEO, Effective Sept. 4
This 8-K filing announces that Pyxis Oncology has appointed Thomas Civik as its permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Mr. Civik …
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
Pyxis Oncology Files Prospectus For Offering 39.2M Common Shares On Behalf Of Selling Shareholders
Pyxis Oncology has filed a prospectus for a secondary offering of up to 39.2 million common shares by existing selling shareholders. This is not a primary offering where the compan…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate
Pyxis Oncology announced its Q2 earnings, reporting a loss of $(0.40) per share, which fell short of analyst expectations by 14.29%. This miss is significant as it indicates the co…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target of $12
Wells Fargo analyst Derek Archila initiated coverage on Pyxis Oncology (PYXS) with an 'Overweight' rating and a $12 price target. This event is significant because new analyst cove…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.